# Safety and Effectiveness of the Sphere-9™ Catheter and Affera™ Ablation System for the Treatment of Ventricular Tachycardia (Sphere VT)

Study · id `cardio:ct-nct07585968` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07585968](<https://clinicaltrials.gov/study/NCT07585968>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT07585968

Browse, organ or system: Heart  
Browse, condition area: Heart rhythm problems  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 260 participants.

## Technical summary

Registry record NCT07585968. Allocation not applicable; no masking; primary purpose treatment. Start 2026-08-17 (actual); primary completion 2028-03 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 260 participants (planned count; ClinicalTrials.gov record NCT07585968, source copy `cardio:ctgov-nct07585968-2026-10-26`, retrieved 2026-10-31)
- Started: 2026-08-17 (actual) (ClinicalTrials.gov record NCT07585968, source copy `cardio:ctgov-nct07585968-2026-10-26`, retrieved 2026-10-31)
- Primary completion: 2028-03 (anticipated) (ClinicalTrials.gov record NCT07585968, source copy `cardio:ctgov-nct07585968-2026-10-26`, retrieved 2026-10-31)
- Completion: 2028-09 (anticipated) (ClinicalTrials.gov record NCT07585968, source copy `cardio:ctgov-nct07585968-2026-10-26`, retrieved 2026-10-31)
- Countries: United States (ClinicalTrials.gov record NCT07585968, source copy `cardio:ctgov-nct07585968-2026-10-26`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07585968-2026-10-26`, retrieved 2026-10-31)

## The registry's words

- Brief title: Safety and Effectiveness of the Sphere-9™ Catheter and Affera™ Ablation System for the Treatment of Ventricular Tachycardia (Sphere VT)
- Condition: Ventricular Tachycardia
- Intervention (Device): Sphere-9 Catheter with the Affera Mapping and Ablation System
- Lead sponsor: Medtronic Cardiac Ablation Solutions
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Ventricular tachycardia (`cardio:ventricular-tachycardia`)
- Registry lists this organization as the lead sponsor: Medtronic Cardiac Ablation Solutions (`cardio:org-medtronic-cardiac-ablation-solutions`)

## Provenance

Content hash: 269a9811404eb022ed9cdee35cfed99d150c1ae0f6e905796c38769aa9adbe0a
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
